Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/29744
Title: SEOM clinical guideline for treatment of kidney cancer (2017).
Authors: 
Keywords: 
Mesh: 
Issue Date: Jan-2018
Citation: Clin Transl Oncol.2018 Jan;(20)1:47-56
Abstract: The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
PMID: 29134564
URI: https://hdl.handle.net/20.500.12530/29744
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5785618.pdf402.2 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.